Alice Pomponio

Alice Pomponio is an impact investor, social innovation entrepreneur, and patient advocate who serves as Vice President Innovation & Impact Investing at American Cancer Society (ACS) and Managing Director, BrightEdge, ACS's venture capital and impact investment arm. She brings extensive experience in life sciences and business and a passion for ACS' lifesaving mission to her leadership role.

Pomponio is an expert in rare disease and precision oncology, and focuses on disruptive technology adoption and companion diagnostic/therapeutic co-development strategies with an eye toward value-based care. Most recently, she was an advisor at Red Sky Partners LLC and the founder and managing director of Accendo. At Red Sky Partners, she advised high-growth life sciences and health tech companies on go-to-market and product value strategies. In 2018, she founded Accendo to accelerate entrepreneurial consumer-facing approaches to patient access and affordability of quality care.

Pomponio held prior strategy and operational leadership roles at Radius Health, AstraZeneca, and Sanofi Genzyme, where she launched multiple U.S. and global specialty products and championed orphan drug policy and health equity initiatives across the globe. She led open innovation and public-private partnerships that have transformed specialty medicines development. Her public sector experience spans innovation, trade, and healthcare policy through roles in the UK Government and U.S. Office of Management and Budget.

Pomponio is a longtime ACS volunteer, including serving as Chair of the Eastern New England Board of Directors and as a National Board Member of the American Cancer Society Cancer Action Network. She is a faculty member at Harvard-MIT HST Sloan Healthcare Ventures, where she teaches biomedical innovation and healthcare entrepreneurship. Pomponio holds a master's degree in public policy from Harvard University and a Bachelor of Science in biology from the Massachusetts Institute of Technology.